Blueprint Medicines (NASDAQ:BPMC) has announced a new drug discovery program to treat fibrolamellar carcinoma (FLC). FLC is a rare liver cancer that usually occurs in young adults who have no history of liver disease, according to the Fibrolamellar Cancer Foundation.
The stock decreased 3.87% or $1.03 during the last trading session, hitting $25.59. About 257,635 shares traded hands or 31.10% up from the average. Blueprint Medicines Corp (NASDAQ:BPMC) has risen 99.55% since February 8, 2016 and is uptrending. It has outperformed by 83.06% the S&P500.
Blueprint Medicines Corporation is a biopharmaceutical company. The company has a market cap of $683.25 million. The Firm focuses on patients with genomically defined diseases driven by abnormal kinase activation. It currently has negative earnings. The Firm focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.